Latigo Posts $69.7M Nine-Month Loss; Material Weakness Persists in First Post-IPO 10-Q
LTGO is trading near its 52-week low of $13.26 (6.8% above the low).
Summary
Latigo's first post-IPO 10-Q shows a $69.7 million nine-month net loss, $401.2 million of cash funding operations into 2029, and a still-unremediated material weakness in internal controls. The quarter also closed out $35.0 million of convertible notes into 1,957,755 shares at the $18.00 IPO price.
Key Events · Earnings and Guidance · LTGO
-
Nine-Month Net Loss of $69.7M
Net loss was $69.7 million for the nine months ended September 30, 2026, including $20.9 million in Q3, versus $71.6 million a year earlier.
-
Cash of $401.2M Funds Operations Into 2029
Cash and cash equivalents stood at $401.2 million at September 30, 2026, including $364.4 million of net IPO proceeds; management estimates this funds operating plans into 2029.
-
Convertible Notes Convert at $18.00 IPO Price
$35.0 million of principal plus $0.2 million of accrued interest converted into 1,957,755 shares at $18.00, producing a $4.6 million loss on extinguishment and a $5.1 million non-cash derivative gain.
-
Material Weakness Still Unremediated
Management concluded disclosure controls were not effective at September 30, 2026 because of the previously disclosed material weakness in segregation of duties over journal entries and account reconciliations; remediation is underway but not complete.
Analysis · LTGO · Life Sciences
Latigo's first quarterly report since its August IPO puts hard numbers on the burn: a $69.7 million net loss for the nine months to September 30 and $20.9 million in Q3 alone, against $401.2 million of cash that management says funds operations into 2029. The quarter also closed out the pre-IPO convertible notes — $35.0 million of principal plus $0.2 million of accrued interest converted into 1,957,755 shares at the $18.00 IPO price, booked as a $4.6 million loss on extinguishment, partly offset by a $5.1 million non-cash gain as the change-of-control derivative was remeasured to zero. Most important for governance is the reaffirmed material weakness in internal controls over segregation of duties in journal entries and account reconciliations, which led management to conclude disclosure controls were not effective at quarter-end; that weakness was previously disclosed in the September 3 10-Q and remains unremediated. Spending mix shifted as the company went public — R&D fell to $56.4 million from $63.7 million while G&A jumped to $15.8 million from $8.3 million. Both lead programs, onzotrigine and LTG-321, are guided to topline data in the second half of 2027, so the cash pile is the story until then.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTGO was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $930.8M. The 52-week trading range was $13.26 to $25.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.